Business
CytoSorb® Receives Marketing Approval in Mexico with Commercialization to Commence with Partner Fresenius Medical Care
CytoSorb® can now be used in Mexico to treat patients with a wide range of conditions including complications from severe COVID-19 infection MONMOUTH
About this update from Cytosorbents Corporation
[{"type":"text","content":"CytoSorb® can now be used in Mexico to treat patients with a wide range of conditions including complications from severe COVID-19 infection\n\n\nMONMOUTH JUNCTION, N.J., March 31, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its CytoSorb cytokine adsorber has been approved to be marketed and sold in Mexico by the country's health authority, COFEPRIS. COFEPRIS, or the Federal Committee for Protection from Sanitary Risks (Comisión Federal para la Protección contra Riesgos Sanitarios) is responsible for regulating the importation of medical devices into the country. \n\n \n \n \n \n \n \n\n \nAs previously announced, Fresenius Medical Care (FMC) maintains the exclusive rights to distribute CytoSorb for acute care and other hospital applications in Mexico. These include indications where cytokines (e.g. sepsis, endocarditis, acute respiratory distress syndrome), bilirubin (e.g. liver disease), or myoglobin (e.g. trauma) are elevated. With this approval, commercial promotional activities and sales of CytoSorb may now officially commence in Mexico.\nMr. Ignacio Castañón, President of Fresenius Medical Care Mexico commented, \"Each year in Mexico, hyperinflammatory conditions such as septic shock, severe lung injury, trauma, and acute flares of chronic liver disease lead to a staggering human and economic toll due to a lack of effective therapies. We are very excited to now bring CytoSorb to doctors and patients throughout Mexico that are dealing with these conditions on a daily basis, particularly now as the number of hospital admissions due to COVID-19 pneumonia are expected to rise dramatically. The FMC Mexico team has been preparing the market and we are ready to go. We hope to have a positive impact on patient care in Mexico with CytoSorb.\"\nMr. Vincent Capponi, Chief Operating Officer of CytoSorbents, stated, \"We are pleased to have successfully achieved the registration of CytoSorb in Mexico and plan to fulfill initial orders from FMC this quarter. Given the COVID-19 pandemic, the approval is timely, providing physicians in Mexico access to an additional tool to fight cytokine storm and in...